#GenScript #CGT #Dr. Craig Mello

GenScript Biotech Global Forum London 2025

The GenScript Biotech Global Forum, which took place in London, marked a significant milestone in the field of cell and gene therapy (CGT). This year's event attracted nearly 400 participants from around the globe, including leading scientists, business executives, and investors. The event, hosted by GenScript Biotech Corporation, served as a platform for discussions on the future of CGT under the theme "THE NEXT ERA OF CGT IS HERE."

One of the highlights of the forum was the keynote speech delivered by Nobel Laureate Dr. Craig Mello. Dr. Mello emphasized the therapeutic potential of RNA interference (RNAi), illustrating its effectiveness with a novel siRNA therapy for preeclampsia. This example showcased how rapidly generated oligonucleotides could potentially tackle a range of diseases, indicating a promising future for RNAi in complementing CGT.

Sherry Shao, the Rotating CEO of GenScript, opened the forum by highlighting the company's commitment to providing end-to-end CGT solutions, from discovery to commercialization. She mentioned how their associate, Legend Biotech, successfully treated over 9,000 patients globally with CARVYKTI, emphasizing the importance of collaboration across academia, industry, and regulatory bodies to push CGT therapies forward.

Key Insights from Industry Leaders

The forum featured additional keynote talks from distinguished speakers, such as Dr. Carl June, who elaborated on CAR-T therapy's advancements and its applications beyond blood cancers. Dr. June, often referred to as the